It has been reported that 4-demethoxy-4′-O-methyldoxorubicin (4-dm-4′-O-methylDX) is more potent than doxorubicin (DX), equally active in some murine leukemias and solid tumors, and almost devoid of cardiotoxicity. We used HPLC to investigate the metabolism and the disposition of this drug in comparison with DX in mice bearing colon 38 adenocarcinoma SC and treated with IV doses of the two drugs that were equiactive and equitoxic (4-dm-4′-O-methylDX 1 mg/kg; DX 10 mg/kg). 4-Dm-4′-O-methylDX was metabolized to a polar metabolite, presumably 4-demethoxyDX, which was eliminated more slowly than the parent drug from all the organs and accounted for 25%–50% of total fluorescence; traces of two metabolites less polar than the parent drug (2% of total fluorescence) were found only at early times in the liver. In DX-treated mice traces of doxorubicinol (1%–3% of total fluorescence) were found in tumor and organs, and two aglycones were detected only at early times in the liver. In plasma both drugs declined biexponentially and 4-dm-4′-O-methylDX was eliminated slightly faster than DX. The rate of elimination of the new analogue from lung, kidney, spleen, and small intestine was faster than that of DX; in heart and liver 4-dm-4′-O-methylDX was detectable for only up to 24 h, while DX was detectable for up to 7 days. In the tumor the kinetics and the elimination patterns of the two drugs were similar. The distribution of 4-dm-4′-O-methylDX, as a percentage of the administered dose, was 1.3–2 times higher than that of DX in the organs and 3 times higher in the tumor, which suggests an improved selectivity of the new analogue for the tumor compared with DX.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Bachur NR, Egorin MJ, Hildebrand RC (1973) Daunorubicin and adriamycin metabolism in the golden Syrian hamster. Biochem Med 8: 352
Bachur NR, Hildebrand RC, Jaenke RS (1974) Adriamycin and daunorubicin disposition in the rabbit. J Pharmacol Exp Ther 191: 331
Bolanowska W, Gessner T (1982) Body residue and metabolism of adriamycin and daunorubicin in control and phenobarbital-pretreated mice. Xenobiotica 12:125
Brown JE, Wilkinson PA, Brown JR (1981) Rapid high-performance liquid chromatographic assay for the anthracyclines daunorubicin and 7-con-O-methylnogarol in plasma. J Chromatogr 226: 521
Chan KK, Chlebowski RT, Tong M, Chen H-SG, Gross JF, Bateman JR (1980) Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 40: 1263
Di Marco A, Casazza AM, Giuliani F, Pratesi G, Arcamone F, Bernardi L, Franchi G, Giardino P, Patelli B, Penco C (1978) Synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4′-epi-adriamycin. Cancer Treat Rep 62: 375
Formelli F, Casazza AM, Di Marco A, Mariani A, Pollini C (1979) Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors. Cancer Chemother Pharmacol 3:261
Formelli F, Pollini C, Casazza AM, Di Marco A, Mariani A (1981) Fluorescence assay and pharmacokinetic studies of 4′-dexydoxorubicin and doxorubicin in organs of mice bearing solid tumors. Cancer Chemother Pharmacol 5: 139
Giuliani FC, Barbieri B, Bellini O, Podestà A, Kaplan NO, Casazza AM (1983) Antitumor activity and cardiotoxicity in mice of a new doxorubicin analog: 4-demethoxy-4′-O-methyldoxorubicin. 13th International Chemotherapy Congress, 12.4 1983, pp 8–17
Marquardt DW (1966) Least-squares estimation of nonlinear parameters, a computer program in FORTRAN IV language. IBM Share Library, 309401
Paul C, Baurain R, Gahrton G, Peterson C (1980) Determination of daunorubicin and its main metabolites in plasma, urine and leukaemic cells in patients with acute myeloblastic leukaemia. Cancer Lett 9: 263
Penco S, Casazza AM, Franchi G, Barbieri B, Bellini O, Podestà A, Savi G, Pratesi G, Geroni G, Di Marco A, Arcamone F (1983) Synthesis, antitumor activity and cardiac toxicity of new 4-demethoxyanthracyclines. Cancer Treat Rep 67: 665
Riggs CE Jr, Benjamin RS, Serpick AA, Bachur NR (1977) Biliary disposition of adriamycin. Clin Pharmacol Ther 22: 234
Schwartz HS (1973) A fluorimetric assay for daunomycin and adriamycin in animal tissues. Biochem Med J 7: 396
Spill J, Splitter G, Lalich J, et al (1980) Adriamycin cardiotoxicity: a comparison with 4-demethoxyadriamycin hydrochloride (NSC 256438). Roltech Scientific Services, Madison, p 1
Wilkinson PM, Israel M, Pegg WJ, Frei E III (1979) Comparative metabolism and excretion of adriamycin in man, monkey and rat. Cancer Chemother Pharmacol 2: 121
The work described in this paper was supported by grant N. 84.00855.44 of the ‘Oncologia’ project of the Consiglio Nazionale delle Ricerche, Rome, Italy
About this article
Cite this article
Formelli, F., Carsana, R. & Pollini, C. Comparative pharmacokinetics and metabolism of doxorubicin and 4-demethoxy-4′-O-methyldoxorubicin in tumor-bearing mice. Cancer Chemother. Pharmacol. 16, 15–21 (1986). https://doi.org/10.1007/BF00255280
- Cancer Research
- Small Intestine